Softgels - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Softgels

An industry leader since 1933, Catalent develops and manufactures over 80% of the world's Rx softgel products with 200+ products on the market in 80+ countries supplied by 11 global sites. Catalent is the world leader of softgel drug delivery technologies, the proven solution to deliver more products and better treatments by reliably solving complex bioavailability, solubility, and formulation challenges.

As the originator of the RP Scherer softgel rotary die process, coupled with over 75 years of global manufacturing expertise, Catalent manufactures softgel products across its network of facilities on 5 continents. Catalent demonstrates its softgel expertise in the following therapeutic areas: Omega-3, Vitamin-D analogs, retinoids, antivirals, and hormones. Catalent has unrivalled breadth and depth of expertise in softgel technologies to solve the toughest drug delivery challenges.

Catalent’s new, breakthrough technologies- OptiShell™ for complex fill formulations, OptiGel Bio™ for macromolecules and OptiGel Lock™ for abuse deterrence- can put even more molecules on a faster path to commercialization. Catalent’s broader range of challenging molecules, combined with deep development expertise, advanced delivery technologies and integrated supply solutions enable better outcomes for a broader range of challenging molecules.

Catalent Pharma Solutions
Website: www.catalent.com
E-mail: media@catalent.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FindPharma Custom Search

Click here